Want to see AU:MAP full AI Analyst Report?
MAP Stock Chart & Stats
AU$0.06
<AU$0.01(2.22%)
At close: 4:00 PM EDT
AU$0.06
<AU$0.01(2.22%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.11
Previous CloseN/A
Volume296.78K
Average Volume (3M)107.15K
Market Cap
AU$34.42M
Enterprise ValueAU$18.34
Total Cash (Recent Filing)AU$7.95M
Total Debt (Recent Filing)AU$4.11M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding717,117,250
10 Day Avg. Volume27,821
30 Day Avg. Volume107,150
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)0.89
Price to Sales (P/S)1.47
P/FCF Ratio-1.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside41.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$19.85M
Bulls Say, Bears Say
Bulls Say
Microbiome Platform BreadthThe platform serves research, clinical decision-making and potential therapeutic development, giving the company several routes to apply its microbiome capabilities. This breadth may support longer-term commercial development and reduce dependence on a single use case as applications mature.
Manageable LeverageLow leverage reduces near-term solvency pressure and leaves the company less exposed to interest costs or debt refinancing than a highly geared business. This balance-sheet characteristic can provide greater flexibility while management works to improve profitability and cash generation.
Revenue Base Above Early YearsRevenue expansion over the longer period indicates that the company has built a larger commercial base than it had in its earlier years. Although the latest period weakened, the accumulated scale provides a foundation from which improved execution and operating leverage could potentially develop.
Bears Say
Persistent Heavy LossesHeavy losses and negative gross profit show that the current revenue base is not yet covering the economics of the business. Persistently deeply negative margins limit internal reinvestment capacity and make a durable path to profitability dependent on substantial operational improvement.
Ongoing Cash ConsumptionRepeated negative operating and free cash flow means the company is consuming cash rather than funding operations and investment internally. Worsening free cash flow in 2026 reinforces the risk that continued activity will require external funding, potentially constraining strategic flexibility.
Deteriorating Latest-year TrajectoryThe latest revenue decline weakens evidence of near-term commercial momentum, while sustained losses have materially eroded equity. Together, these trends indicate pressure on both operating performance and the capital base, increasing the need for a credible turnaround in growth and profitability.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$34.42M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Mar 03, 2027 which is in 161 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Sep 01, 2026. The company reported -AU$0.016 earnings per share for the quarter, missing the consensus estimate of -AU$0.006 by -AU$0.01.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 717,117,250 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.016 in its last earnings report, missing expectations of -AU$0.006. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.08 (41.67% Upside)
AU$0.08 (41.67% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth AU$72.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.08
▲(41.67% Upside)
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―